Grant round · GrantConnect grant opportunity
Grant round GO7555
Awards in this round describe their activity in more than one way. The most common:
- “A randomized Phase 3 trial comparing stereotactic body radiotherapy (SBRT) vs conventional external beam radiotherapy (cEBRT) for individuals with painful non-spine bone metastases” (1 award)
- “Hypofractionated Alternative Radiation with Modulation of Neoadjuvant/perioperative immunotherapy in Sarcoma” (1 award)
- “OPT-PEMBRO: Optimizing adjuvant prescription of pembrolizumab in patients with early-stage triple-negative breast cancer achieving pathologic complete response after standard neoadjuvant chemotherapy and pembrolizumab” (1 award)
- “OPTIMA Premenopausal Extension” (1 award)
- “Phase 3 trial testing the safety and effectiveness of delivering simultaneous integrated boost radiotherapy (RT) in 1-week compared with the standard 3- week RT schedule in people with early breast cancer” (1 award)
$13m
whole-of-term value of 6 awards to 4 named recipients, published 2026-02-23 to 2026-06-22
$2.0m falls in 2026-27, from 6 active awards. estimate: annualised
A grant round is a grant opportunity on GrantConnect: an open or targeted call for applications under published guidelines. GrantConnect’s award lists give the opportunity’s ID but not its title; search GrantConnect for GO7555 to read its guidelines.
By agency
| Granting agency | Awards | Total value |
|---|---|---|
| Department of Health, Disability and Ageing | 6 | $13m |
Recipients, largest first
Recipients who are individuals, and awards that name no single recipient, are counted above but not listed, here or in the CSV. Why The bulk download has every award, with individuals flagged.
| Recipient | Awards | Total value |
|---|---|---|
| Breast Cancer Trials | 2 | $5.4m |
| Trans Tasman Radiation Oncology Group Limited | 2 | $4.2m |
| The University of Queensland | 1 | $2.0m |
| Australia and New Zealand Sarcoma Association Limited | 1 | $1.4m |